Hepatitis B Virus Nucleic Acid Detection Kit (PCR-Fluorescence Probe Method): Key Points for Registration Review and Market Compliance

Product Classification and Registration Pathway

The Hepatitis B Virus Nucleic Acid Assay Kit (PCR-Fluorescent Probe Method) belongs to Class III medical devices within in vitro diagnostic reagents and requires registration with the National Medical Products Administration (NMPA). According to the "Measures for the Registration Administration of In Vitro Diagnostic Reagents," this product shall submit registration materials under the category of "used for blood screening and quantitative detection of pathogen nucleic acids," including product technical requirements, analytical performance evaluation, clinical evaluation materials, and risk analysis reports.

Performance Evaluation and Clinical Trial Requirements

Analytical performance evaluation shall cover indicators such as sensitivity, specificity, precision, linear range, and anti-interference capability. For example, precision evaluation typically includes intra-batch precision, inter-batch precision, and total precision, and shall be verified using clinical samples at no fewer than two concentration levels. Clinical trials shall select no fewer than three clinical trial institutions, adopt comparison with marketed products of the same type or reference methods (such as sequencing, digital PCR), and the sample size shall meet statistical requirements and shall include specimens of different genotypes and different viral loads. The trial conclusions shall clearly specify key parameters such as the concordance rate and quantitative bias of the kit.

Production Quality Control and System Requirements

Manufacturing enterprises shall establish a quality management system compliant with the "Good Manufacturing Practice for Medical Devices" and covering the entire process, including raw material procurement, primer and probe synthesis, reagent preparation, aliquoting, and finished product testing. Key materials (such as enzymes, dNTPs, and fluorescent probes) shall have specified acceptance criteria, and suppliers shall be periodically verified. Before release of finished products, batch-by-batch testing shall be conducted, with items including appearance, fill volume, accuracy, limit of detection, and concordance rate of positive reference materials. In addition, product stability study files shall be established, including long-term stability, accelerated stability, and transport simulation stability data.

Post-Market Surveillance and Adverse Event Reporting

After marketing, enterprises shall continuously collect adverse events during product use, such as abnormal false negative/false positive rates and out-of-limit quantitative bias, and shall report them promptly in accordance with the requirements of the "Measures for the Administration of Medical Device Adverse Event Monitoring and Re-evaluation." At the same time, they shall cooperate with regulatory authorities in conducting unannounced inspections and supervisory sampling. For any change to the kit instructions, a registration licensing item change or filing application shall be submitted in accordance with regulations.